Actively Recruiting
Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN Platforms for Oncology Patients
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-08-29
3149
Participants Needed
3
Research Sites
8 weeks
Total Duration
On this page
Sponsors
A
Assistance Publique - Hôpitaux de Paris
Lead Sponsor
A
AuraGen Aesthetics LLC
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying how high-throughput genomic sequencing platforms, SeqOIA and AURAGEN, affect cancer patient care and treatment decisions. This observational study gathers clinical and organizational data to assess key factors such as the quality of patient information, turnaround times for results, and overall quality of care. The project supports public health decisions and helps plan future genomic medicine services in France. The study collects data from patients with cancer who are referred for genomic sequencing validated by a multidisciplinary tumor board since January 1, 2021. Clinical and molecular decisions come from national tumor boards documented via digital tools, while additional clinical data are taken from hospital medical records before and after sequencing. The study measures includes turnaround time for sequencing results and treatment recommendations following multidisciplinary meetings. Participants contribute through the collection of clinical data and tumor board reports, with key outcome measures including the time from sample arrival to analysis, time from sequencing to report signing, and time until treatment recommendations are made. The study monitors these indicators over periods of 8 weeks and 6 months to understand how genomic information affects care pathways. This research aims to optimize genomic workflows and guide national health strategies for cancer care.
CONDITIONS
Brief Title
Performance Indicators and Impact on the Care Pathway of Sequencing on the SeqOIA and AURAGEN (Seqogen) Platforms for Oncology Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with cancer and referred for high-throughput sequencing
- Sequencing pre-indication validated by a multidisciplinary tumor board since January 1, 2021
- Consent given for reuse of medical and genomic data for research purposes
You will not qualify if you...
- Opposition to reuse of medical and genomic data
- Unvalidated sequencing pre-indication by multidisciplinary tumor board
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote) for eligibility assessment and consent
Duration - Up to 8 weeks
Participants undergo genomic sequencing and related diagnostic procedures to assess tumor characteristics.
Visits as needed for sample collection and sequencing processes
Duration - Up to 6 months
Participants are observed to evaluate the impact of genomic sequencing on treatment decisions and care pathways.
Clinical data collected from medical records throughout follow-up period
Trial Site Locations
Total: 3 locations
1
Centre Leon Berard
Lyon, France, 69000
Actively Recruiting
2
APHP Hôtel Dieu URC Economie de la sante /URC ECO
Paris, France, 75004
Active, Not Recruiting
3
HOPITAL AP-HP Cochin
Paris, France, 75005
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here